<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02401243</url>
  </required_header>
  <id_info>
    <org_study_id>GLARGL07496</org_study_id>
    <secondary_id>U1111-1168-5158</secondary_id>
    <nct_id>NCT02401243</nct_id>
  </id_info>
  <brief_title>Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients</brief_title>
  <acronym>TITRATION</acronym>
  <official_title>A Pilot Descriptive Canadian, Multicenter, Open-label, Randomized Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      The primary objective of this study is to obtain efficacy and safety descriptive data on 2
      different titration algorithms: the INSIGHT titration algorithm (self-titration of 1
      unit/day) and the EDITION trial algorithm with insulin glargine 300 units/mL when given as
      basal insulin in uncontrolled type 2 diabetes mellitus (T2DM) patients on basal insulin with
      or without non-insulin anti-hyperglycemic agent (NIAHA) or in insulin naïve patients.

      Secondary Objective:

      The secondary objective is to gain additional efficacy and safety data (glycated hemoglobin
      [A1C], fasting plasma glucose [FPG], 7-point self-measure plasma glucose [SMPG], insulin dose
      and weight) and determine patient related outcome and health care professional satisfaction
      as it pertains to each titration regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration is approximately 14 weeks (2 weeks screening and 12 weeks treatment)
      with a 2-day safety follow-up and a study extension of 12 weeks for eligible patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients reaching fasting SMPG ≤5.6 mmol/L without nocturnal (midnight to 6:00 am) hypoglycemia (confirmed or symptomatic or severe)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with adverse events</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">253</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (INSIGHT titration algorithm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INSULIN GLARGINE (U300): self-titration of insulin glargine 300 units/mL (U300) will be increased daily by 1 unit until fasting SMPG reaches the target range of 4.4 to 5.6 mmol/L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (EDITION titration algorithm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INSULIN GLARGINE (U300): titration of insulin glargine 300 units/mL (U300) will be adjusted weekly or not more than every 3 days to achieve the target range of fasting SMPG of 4.4 to 5.6 mmol/L</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INSULIN GLARGINE (U300)</intervention_name>
    <description>Pharmaceutical form: pre-filled disposable pen
Route of administration: subcutaneous</description>
    <arm_group_label>Cohort 1 (INSIGHT titration algorithm)</arm_group_label>
    <arm_group_label>Cohort 2 (EDITION titration algorithm)</arm_group_label>
    <other_name>HOE901</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients with type 2 diabetes mellitus.

          -  Patients who are ≥18 years of age.

          -  Treated for diabetes for at least 6 months.

               -  If on basal insulin, stable for at least 3 months prior to screening visit on
                  their basal insulin treatment(s) (±20% total insulin dose)

               -  If on NIAHA, stable for at least 8 weeks prior to screening visit on their
                  NIAHA(s) (no change in dose or initiation of new NIAHAs).

          -  Patients on uncontrolled basal insulin (insulin glargine, normal protamine Hagedorn
             [NPH], detemir) +/ NIAHAs with an A1c &gt;7.0% and ≤10% or uncontrolled on NIAHAs
             (insulin naïve patients) with an A1c &gt;7.0% and ≤11%.

          -  Signed informed consent form.

        Exclusion criteria:

          -  Patients with type 1 diabetes mellitus (T1DM).

          -  Nightshift worker.

          -  Female patients who are pregnant or lactating.

          -  Treatment with an insulin other than basal insulin (premixes, rapid insulin, fast
             acting insulin analogues) within the previous 3 months.

          -  Patients with less than 1 year history of diabetes.

          -  Patients unwilling to inject insulin or perform self-monitoring blood glucose.

          -  Current alcohol or drug abuse.

          -  Patients unlikely to comply with the protocol and complete the study eg, uncooperative
             attitude, inability to return for follow-up visits.

          -  Patients with active cancer or any other diseases or conditions which in the opinion
             of the Investigator would make the patient unsuitable for participation in the study.

          -  Any clinically significant laboratory findings that in the judgment of the
             Investigator would preclude safe completion of the study.

          -  Known allergies to study drugs.

          -  Participation in another clinical study.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 124001</name>
      <address>
        <city>Abbotsford</city>
        <zip>V2S3N5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124013</name>
      <address>
        <city>Brampton</city>
        <zip>L6T4V3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124008</name>
      <address>
        <city>Burlington</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124024</name>
      <address>
        <city>Burnaby</city>
        <zip>V5G1T4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124015</name>
      <address>
        <city>Collingwood</city>
        <zip>L9Y1W3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124025</name>
      <address>
        <city>Corunna</city>
        <zip>N0N 1G0</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124019</name>
      <address>
        <city>Etobicoke</city>
        <zip>M9V4V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124021</name>
      <address>
        <city>Hamilton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124011</name>
      <address>
        <city>Laval</city>
        <zip>H7T 2P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124005</name>
      <address>
        <city>Levis</city>
        <zip>G6W5M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124018</name>
      <address>
        <city>London</city>
        <zip>N5W 6A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124003</name>
      <address>
        <city>Oshawa</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124010</name>
      <address>
        <city>Quebec</city>
        <zip>G1W4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124012</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124007</name>
      <address>
        <city>Sarnia</city>
        <zip>N7T 4R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124002</name>
      <address>
        <city>Saskatoon</city>
        <zip>S7K 3H3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124023</name>
      <address>
        <city>Sherbrooke</city>
        <zip>J1G5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124009</name>
      <address>
        <city>Smiths Falls</city>
        <zip>K7A4W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124017</name>
      <address>
        <city>Strathroy</city>
        <zip>N7G1Y7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124020</name>
      <address>
        <city>Toronto,</city>
        <zip>M8V3X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124006</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124026</name>
      <address>
        <city>Vancouver</city>
        <zip>V6J1S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124004</name>
      <address>
        <city>Victoria</city>
        <zip>V8V4H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124014</name>
      <address>
        <city>Winnipeg</city>
        <zip>R2V4W3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124016</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3E 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2015</study_first_submitted>
  <study_first_submitted_qc>March 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2015</study_first_posted>
  <last_update_submitted>March 25, 2016</last_update_submitted>
  <last_update_submitted_qc>March 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

